Bectumomab
Bectumomab
Bectumomab (pronunciation: bek-tuh-moh-mab) is a type of monoclonal antibody used in cancer treatment.
Etymology
The term "Bectumomab" is derived from the Latin roots "Bectu", meaning "to strike", and "mab", an abbreviation for "monoclonal antibody". This reflects the drug's function as a targeted treatment for cancer.
Usage
Bectumomab is used in the treatment of certain types of cancer, including non-Hodgkin lymphoma and leukemia. It works by binding to specific proteins on the surface of cancer cells, thereby marking them for destruction by the body's immune system.
Related Terms
- Monoclonal antibody: A type of protein made in the lab that can bind to substances in the body, including cancer cells.
- Non-Hodgkin lymphoma: A type of cancer that originates in the lymphatic system, the body's disease-fighting network.
- Leukemia: A type of cancer of the body's blood-forming tissues, including the bone marrow and the lymphatic system.
Side Effects
Like all medications, Bectumomab can cause side effects. These may include nausea, fatigue, and fever. More serious side effects can include anemia, neutropenia, and thrombocytopenia.
See Also
External links
- Medical encyclopedia article on Bectumomab
- Wikipedia's article - Bectumomab
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski